Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma. [electronic resource]
Producer: 20201123Description: 4211 p. digitalISSN:- 2045-2322
- Animals
- Benzamides -- pharmacology
- Dasatinib -- pharmacology
- Disease Models, Animal
- Drug Therapy, Combination
- Female
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Morpholines -- pharmacology
- Neurofibromin 2 -- genetics
- Neuroma, Acoustic -- drug therapy
- Protein Kinase Inhibitors -- pharmacology
- Pyrimidines -- pharmacology
- Receptor, EphA1 -- metabolism
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.